Antagonism of the antithrombotic and anti- @entity731 actions of @entity117 by @entity13586 in the XXXX -fed @entity95 .

@entity1 @entity13586 @entity49662 @entity731 @entity117 @entity95 @entity715 @entity1281 @entity165 @entity12050
BACKGROUND AND PURPOSE: Most @entity1 at elevated cardiovascular risk receive long-term @entity117 ( @entity1281 ) anti-platelet treatment. The present study specifically addresses the pharmacological interactions between selective @entity12050 inhibitors and @entity1281 and the possible consequences for the @entity715 risk during long-term treatment. EXPERIMENTAL APPROACH: New Zealand white @entity95 were fed a standard laboratory diet supplemented with 1% @entity165 (CON) for 12 weeks. Age-matched control @entity95 were fed the same standard diet without addition of @entity165 (SD). @entity95 were randomly assigned to one of the following groups: @entity13586 (ROFE, 25 mg  kg     , @entity49662 ), @entity117 ( @entity1281 , 5 mg  kg     , @entity49662 ) or a combination of both ( @entity1281 + ROFE). At the end of the feeding period, the severity of @entity731 formation was assessed in the aorta. @entity715 formation was assessed in the left carotid artery using a modified Folts procedure. KEY RESULTS: Treatment of @entity165 -fed @entity95 with @entity1281 significantly reduced plaque formation. This reduction in lesion size was not observed in animals treated with the combination of @entity13586 and @entity1281 . In the modified Folts model, treatment with either @entity13586 or @entity1281 increased the total blood flow above that of untreated animals. This increase was statistically significant in the case of @entity1281 , while cotreatment with @entity13586 abolished this @entity1281 effect completely and reduced the total flow rate to the levels seen in untreated hypercholesterolaemic controls. CONCLUSIONS: @entity12050 inhibition by @entity13586 attenuates the antithrombotic and anti- @entity731 effects of @entity1281 during long-term treatment in @entity165 -fed @entity95 .
